Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 3/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29979002 | 0.97 | HRH3 (0.39) | HRH3NOS3NOS1NOS2SIGMAR1 | |
| Bromide SCHEMBL20551357 | 0.86 | HRH3 (0.42) | HRH3NOS3NOS1NOS2 | |
| Bromide SCHEMBL31466403 | 0.86 | CYP3A4 (0.31) | — | |
| SCHEMBL18091474 | 0.83 | HRH3 (0.44) | HRH3NOS3NOS1NOS2SIGMAR1 | |
| SCHEMBL29979433 | 0.76 | HRH3 (0.33) | HRH3NOS3NOS1NOS2 | |
| SCHEMBL29979229 | 0.75 | DRD2 (0.32) | — | |
| SCHEMBL1255097 | 0.75 | ALOX15 (0.57) | HRH3NOS3NOS1NOS2SIGMAR1 | |
| SCHEMBL5151766 | 0.75 | KDM4E (0.41) | HRH3NOS3NOS1NOS2SIGMAR1 | |
| SCHEMBL954044 | 0.75 | HRH3 (0.38) | HRH3NOS3NOS1NOS2SIGMAR1 | |
| SCHEMBL1473652 | 0.75 | ALDH1A1 (0.43) | HRH3NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110770214-B | Heterocyclic P2X7 antagonists | 布雷耶疗法有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | BREYE THERAPEUTICS APS (DK) | 2023-04-11 | — | — | US | disclosed |
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | BREYE THERAPEUTICS APS (DK) | 2020-02-20 | — | — | US | disclosed |
| CN-110770214-A | Heterocyclic P2X7 antagonists | 阿克萨姆股份公司 | 2020-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200055831-A1 | HETEROCYCLIC P2X7 ANTAGONISTS | P2RY1, P2RX1, P2RX3 | SIGMAR1 138/4885HRH3 20/4885NOS3 2623/4885 |
| US-11623919-B2 | Heterocyclic P2X7 antagonists | P2RY1, P2RX1, P2RX3 | SIGMAR1 138/4885HRH3 20/4885NOS3 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.